RESafety

Requirements Engineering for Safety

PhD Student: Moniky Ribeiro
Advisor: Prof. Jaelson Castro
Co-advisor: Prof. Ricardo Argenton

RESafety

The 7-Step Process



RESafety

Insulin Infusion Pump (IIP) Example



Figure 1 – Overview of the Insulin Infusion Pump System [1]



Insulin Infusion Pump (IIP)

Types of Insulin Delivery

- Basal: A constant, low-level infusion throughout the day and night. Example: Up to five programmable basal profiles over 24h.

- Bolus: A larger dose triggered by meals or to correct high blood sugar. Delivered manually or based on user programming.

Insulin Infusion Pump (IIP)

Components of a Typical Pump

- User interface: LCD screen and audio alarms.
- Hardware parts: Microprocessor, battery, infusion mechanism, insulin reservoir, and catheter.



Figure 2 – Retrieved from [2]

Insulin Infusion Pump (IIP)

Safety implications

- Main accidents:
  - Overdose → Hypoglycemia (low blood sugar)
  - Underdose → Hyperglycemia (high blood sugar)

- Other accidents: skin infections, battery failure, or device malfunction, etc.

RESafety

BPMN Diagram of the Process



Link to the IIP Example Analysis:
https://docs.google.com/document/d/1ubwn6wNi_9WhdnSAAQxyeq6hOL1R7Ldqu0FSG1769yc/edit?tab=t.0





RESafety

STEP 1 - Define the scope of the Safety-Critical System







RESafety

STEP 1 - Define the scope of the Safety-Critical System

Subprocess-> Define general concerns

STEP 1 - Define the scope of the SCS

1.1 General Concerns

1.1.1 Analysis Objectives

The purpose of this analysis is to model an Insulin Infusion Pump (IIP) through the iterative RESafety process, generating successive refinements of the system's safety analysis artifacts.

1.1.2 System Definition

The Insulin Infusion Pump (IIP), a safety-critical system, is designed to support the treatment of Type 1 Diabetes Mellitus. Automated IIPs enhance treatment flexibility by managing multiple stages of insulin delivery, effectively mimicking physiological responses. These devices administer both rapid-acting (bolus) and continuous (basal) insulin doses.

1.1.3 Resources Needed for Analysis

- **Articles**: Martinazzo (2022); Martins et al. (2015); Zhang et al. (2011, 2010); Bas (2020); Gonzalez Atienza et al. (2024)
- **Books**: Leveson & Thomas (2018); Martins & Gorschek (2021)
- General Guidelines and Manuals

1.1.4 System Boundary

The system boundary encompasses activities from the moment the patient configures the infusion settings until the correct dosage is delivered via the catheter.

1.1.5 Components

- Patient
- Infusion Insulin Pump
- Infusion Set







RESafety

STEP 1 - Define the scope of the Safety-Critical System

Subprocess-> Define safety concerns

STEP 1 - Define the scope of the SCS

1.2 Safety Concerns

1.2.1 Identify Accidents

- **A1** - Risk of death
- **A2** - Risk of injury

1.2.2 Identify System-Level Hazards

- **H1 -** Hypoglycemia [A1, A2]
- **H2 -** Hyperglycemia [A2]

1.2.3 Identify System Constraints

- **SC-01 -** The system must not administer insulin in excess of the prescribed dose or in unintended circumstances. [H1]
- **SC-02 -** The system must ensure that the prescribed insulin dose is delivered at the correct time and in the correct amount. [H2]

1.2.4 Identify the responsibilities

Entity	Responsability
E1 – Patient (Human Controller)	R-01: Ensure that infusion settings are correctly configured and correspond to the medical prescription [SC-01, SC-02] R-02: Verify that the device interface confirms the programmed dose before administration [SC-01]
E2 - Insulin Infusion Pump	...
E3 - Infusion Set	...
E4 - Patient (Human Body)	...

1.2.5 Other Artifacts

- *Not applicable*

RESafety

STEP 2 - Define iStar4Safety Models (SD and SR)





STEP 2 - Define iStar4Safety Models

SD Model



RESafety

STEP 2 - Define iStar4Safety Models (SD and SR) -

Subprocess-> Develop Strategic Rationale (SR) model



STEP 2 - Define iStar4Safety Models

SD and SR Models







RESafety

STEP 3 - Define the Control Structure

STEP 3 - Define the Control Structure





RESafety

STEP 4 - Identify Unsafe Control Actions (UCAs)





STEP 4 - Define UCAs

Control Action	From/To	Not Providing Causes Hazard	Providing Causes Hazard	Too Early, Too Late, Out of Order	Stopped Too Soon, Applied Too Long
Program insulin dosage (R-1)	Patient / Infusion Pump	**UCA-01:** Patient does not provide "Program insulin dosage" when insulin is required, leading to underdose [H1]	**UCA-02:** Patient provides "Program insulin dosage" with a value higher than prescribed, leading to overdose [H2] **UCA-03:** Patient provides "Program insulin dosage" with a value lower than prescribed, leading to underdose [H1]	**UCA-04:** Patient provides "Program insulin dosage" too late, leading to hyperglycemia [H1] **UCA-05:** Patient provides "Program insulin dosage" too early, leading to premature insulin administration and resulting in hypoglycemia [H2]	*Not applicable*

Hazard Cause
HC-01: The pump is misplaced or inaccessible to the patient.[H2]





RESafety

STEP 5 -
Define controller constraints

STEP 5 - Define Controller Constraints

Unsafe Control Action	Controller Constraint
UCA-01: Patient does not provide "Program insulin dosage" when insulin is required, leading to underdose. [H1]	**C-01:** The patient must program the insulin dosage whenever insulin is required, according to clinical guidance. [UCA-01]
UCA-02: Patient provides "Program insulin dosage" with a value higher than prescribed, leading to overdose. [H2]	**C-02:** The patient must ensure the programmed insulin dosage does not exceed the value prescribed by the physician. [UCA-02]
UCA-03: Patient provides "Program insulin dosage" with a value lower than prescribed, leading to underdose. [H1]	**C-03:** The patient must verify that the programmed dosage meets the minimum prescribed threshold to avoid underdosing. [UCA-03]
UCA-04: Patient provides "Program insulin dosage" too late, leading to hyperglycemia. [H1]	**C-04**: The patient must program the insulin dosage in a timely manner, according to the prescribed administration window. [UCA-04]
UCA-05: Patient provides "Program insulin dosage" too early, leading to premature insulin administration and resulting in hypoglycemia. [H2]	**C-05:** The patient must not program the insulin dosage before the appropriate physiological or dietary conditions occur. [UCA-05]
HC-01: The pump is misplaced or inaccessible to the patient.	**C-06:** The insulin pump must always be correctly placed and readily accessible to the patient.

RESafety

STEP 6 - Analyze Loss Scenarios and derive safety requirements





STEP 6 - Analyze Loss Scenarios and derive safety requirements

UCA	Loss Scenario (LS)	Safety Requirement (SR)
UCA-01: Patient does not provide "Program insulin dosage" when insulin is required, leading to underdose [H1]	**LS-01:** The patient forgets to program the dose after the meal, resulting in hyperglycemia. [UCA-01] *Martinazzo (2022)* **LS-02:** The system does not issue a reminder to program the dose after detecting a meal event. [UCA-01] *Ribeiro et al. (2024)*	**SR-01:** The system shall generate an alert if insulin is not programmed within 15 minutes after a meal is detected. [LS-01] *Zhang et al. (2011)* **SR-02:** The interface must maintain a visible warning if no insulin programming is detected post-meal. [LS-02] *Ribeiro et al. (2024)*
…	…	…

Hazard Cause	Loss Scenario	Safety requirement
HC-01: The pump is misplaced or inaccessible to the patient.	**LS-11**: The patient is in a critical condition and does not remember where the pump was placed.	**SR-10**: The pump must have an associated mobile application that allows a "locate pump" function to trigger an audible alarm when activated.

RESafety

STEP 7 - Update iStar4Safety Models





STEP 7 - Update iStar4Safety Models

SD and SR Model

7.1 SD Model (The same)



7.2 SR Model







RESafety

"Another iteration" Exclusive Gateway

Vs

"Final Safety Analysis Reported" End Event

References

1. A. Martinazzo, L. E. G. Martins, S. V. Aredes and T. S. Cunha, "Risk Management of a Low-cost Insulin Infusion Pump: A Case Study with a Brazilian Company," 2021 IEEE 34th International Symposium on Computer-Based Medical Systems (CBMS), Aveiro, Portugal, 2021.
2. WikEM. (n.d.). Insulin infusion device complication. Retrieved June 3, 2025, from http://medbox.iiab.me/modules/en-wikem/wiki/Insulin_infusion_device_complication.html

Thanks!

Contacts:

Moniky Ribeiro-> monikyr@gmail.com **or**
smsr@cin.ufpe.br

Jaelson Castro-> jbc@cin.ufpe.br